Testing RC48 for ovarian cancer returning after platinum treatment
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug, RC48, for people with ovarian cancer that came back after responding well to platinum chemotherapy. RC48 targets the HER2 protein on cancer cells, which may stop the tumor from growing. Researchers want to see if it's safe and works better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have ovarian, fallopian tube, or primary peritoneal cancer that has come back after platinum-based chemo, and you've had between 1 and 4 previous treatments.
- Your tumor has a specific protein called HER2 (levels 1+, 2+, or 3+). You need to provide a tissue sample to confirm this.
- You have not had prior treatment with a HER2-targeting drug (like trastuzumab or other ADC drugs).
- You are in generally good health (able to do daily activities) and have adequate organ function (kidneys, liver, blood).
- You have at least one measurable tumor (by CT or MRI), and you can get pregnant so you need a negative pregnancy test and birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called RC48, alone or with envafolimab, for men with a specific type of advanced prostate cancer that has not responded to standard treatments. It aims to see if this combination can shrink tumors or slow disease progression.
This trial is testing a new drug, LBL-024, combined with chemotherapy (with or without a targeted therapy called bevacizumab) for ovarian cancer that has stopped responding to standard platinum-based treatment. The goal is to see if this combination can effectively shrink tumors and slow the disease's progression.
This trial tests a combination of disitamab vedotin, platinum chemotherapy, and bevacizumab as first treatment for high-risk ovarian cancer that has a protein called HER2. The goal is to see if this therapy helps control the cancer and keeps it from growing.
This study tests whether a new targeted drug (distamab vedotin) combined with standard chemo (carboplatin) works better than chemo alone for women with advanced ovarian cancer that has high levels of HER2. It is for women who have not had chemotherapy yet and have already had surgery to remove the tumor.
This trial tests a new drug combination (trastuzumab rezetecan plus carboplatin) with or without bevacizumab, compared to standard chemotherapy, for ovarian cancer that has come back after platinum-based treatment. It aims to see if this combination works better than the usual options.
This trial tests whether combining the drug RC48 with chemotherapy can help people whose HER2-positive advanced breast cancer has stopped responding to a prior type of antibody-drug conjugate (ADC) therapy. It may offer a new treatment option for those whose cancer has progressed after previous treatments.
Hear when a new Ovarian Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.